Current Status and Challenges in Rotigotine Delivery

Author(s): Shadab Md*, Shahid Karim, Sanggetha R. Saker, Ooi A. Gie, Lim C. Hooi, Phua H. Yee, Alvin W.C. Kang, Chen K. Zhe, Ng Ian, Hibah M. Aldawsari, Khaled M. Hosny, Nabil A. Alhakamy*.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 19 , 2020

Become EABM
Become Reviewer

Abstract:

Rotigotine is a non-ergoline, high lipophilic dopamine agonist. It is indicated as the first-line therapy for Parkinson's disease (PD) and Restless Leg Syndrome (RLS). However, the precise mechanism of rotigotine is yet to be known. Rotigotine has similar safety and tolerability to the other oral non-ergolinic dopamine antagonists in clinical trials, which include nausea, dizziness and somnolence. Neupro® was the first marketed transdermal patch formulation having rotigotine. The transdermal delivery system is advantageous as it enables continuous administration of the drug, thus providing steady-state plasma drug concentration for 24-hours. Intranasal administration of rotigotine allows the drug to bypass the blood-brain barrier enabling it to reach the central nervous system within minutes. Rotigotine can also be formulated as an extended-release microsphere for injection. Some challenges remain in other routes of rotigotine administration such as oral, parenteral and pulmonary, whereby resolving these challenges will be beneficial to patients as they are less invasive and comfortable in terms of administration. This review compiles recent work on rotigotine delivery, challenges and its future perspective.

Keywords: Rotigotine, microemulsion, microspheres, nanoparticles, transdermal delivery, Parkinson's Disease (PD).

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 19
Year: 2020
Page: [2222 - 2232]
Pages: 11
DOI: 10.2174/1381612826666200316154300
Price: $65

Article Metrics

PDF: 20